Urinary angiotensinogen is a marker for tubular injuries in patients with type 2 diabetes

Takahiro Terami¹
Jun Wada¹
Kentaro Inoue¹
Atsuko Nakatsuka¹,²
Daisuke Ogawa¹,²
Sanae Teshigawara¹
Kazutoshi Murakami¹,³
Akihiro Katayama¹
Jun Eguchi¹
Hirofumi Makino¹

¹Department of Medicine and Clinical Science, ²Department of Diabetic Nephropathy, ³Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Purpose: Urinary angiotensinogen has been reported as a marker for the activation of intrarenal renin–angiotensin system (RAS) in various kidney diseases. To investigate the importance of urinary angiotensinogen in diabetic nephropathy, we compared the urinary levels of angiotensinogen, albumin, and α1-microglobulin.

Materials and methods: Japanese patients with type 2 diabetes at various stages of nephropathy (n=85) were enrolled, and we measured albumin/creatinine ratio (ACR) and urinary excretion of angiotensinogen and α1-microglobulin. We also compared the clinical data of the patients treated with or without angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (RAS inhibitors [+], n=51; RAS inhibitors [−], n=34).

Results: Urinary angiotensinogen levels positively correlated with ACR (r=0.367, P=3.84×10⁻⁴) and urinary α1-microglobulin (r=0.734, P=1.32×10⁻⁵), while they negatively correlated with estimated glomerular filtration rate (eGFR) (r=−0.350, P=1.02×10⁻³) and high-density lipoprotein cholesterol (r=−0.216, P=0.049). Multiple regression analysis was carried out to predict urinary angiotensinogen levels by employing eGFR, ACR, and urinary α1-microglobulin as independent variables; only urinary α1-microglobulin entered the regression equation at a significant level. Although ACR was higher in the RAS inhibitors (+) group, urinary α1-microglobulin and angiotensinogen did not show significant increase in the RAS inhibitors (+) group.

Conclusion: Urinary angiotensinogen is well correlated with urinary α1-microglobulin and reflected the tubular injuries which may be associated with the intrarenal RAS activation in patients with type 2 diabetes.

Keywords: diabetic nephropathy, urinary biomarkers, renin–angiotensin system, angiotensinogen, α1-microglobulin, albumin

Introduction
The role of local renin–angiotensin system (RAS) in kidney tissues in the pathophysiology of diabetic nephropathy has been emphasized.¹ The hyporeninemic hypoaldosteronism observed along with the progression of diabetic nephropathy and the efficacy of RAS inhibitors reducing the albuminuria in such patients also supports the notion that intrarenal RAS plays an important role in the progression of diabetic nephropathy. Sawaguchi et al² reported that the baseline urinary excretion of angiotensinogen (10–150 µg/gCr) positively correlated with albumin/creatinine ratio (r=0.77, P<0.001) and urinary β₂-microglobulin (r=0.72, P<0.001) in type 2 diabetes patients with normo- and microalbuminuria. Furthermore, urinary angiotensinogen significantly correlated with annual decline of estimated glomerular filtration rate (eGFR) (r=−0.51, P<0.001), and a higher level of urinary angiotensinogen is a risk for the progression of...
diabetic nephropathy.2 Most of the clinical studies measuring urinary angiotensinogen and albumin levels demonstrated the strong correlation between two proteins with comparable molecular weight (67 and 65 kDa). Thus, it is still unknown whether urinary angiotensinogen is a marker of impairment of glomerular permeability like albumin/creatinine ratio (ACR), a marker of tubular interstitial injuries or a biomarker for the activation of intrarenal RAS in diabetic nephropathy. In this study, we measured ACR, urinary α1-microglobulin, and urinary angiotensinogen levels in patients with various stages of diabetic nephropathy and investigated the clinical significance of urinary angiotensinogen in diabetic nephropathy.

Materials and methods

Patients

We recruited Japanese patients with type 2 diabetes (n=85, 62.9 ± 11.3 years) into this study at Okayama University Hospital. The current study is a substudy of the report and shared the recruited patients.3 Patients were treated with oral hypoglycemic agents (n=48) and insulin (n=49). The patients with hypertension (n=59) were treated with angiotensin II receptor blockers (ARB; n=49), angiotensin-converting enzyme inhibitors (ACEI; n=13), calcium channel blockers (n=34), and diuretics (n=11). We compared the clinical data of the patients treated with ARB or ACEI (RAS inhibitors [+]; n=51) without ARB and ACEI (RAS inhibitors [−]; n=34). Dyslipidemia was noted in 53 patients; most of these patients were treated with statins (n=45). The patients with eGFR <15 mL/min/1.73 m² or those undergoing dialysis were excluded from the current study. All recruited patients with type 2 diabetes agreed to measure urinary levels of α1-microglobulin and angiotensinogen. The study was conducted in accordance with the ethical principle of the Declaration of Helsinki and was approved by the ethical committee of Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences. Written informed consent was obtained from each patient.

Blood sampling and assays

We measured overnight fasting serum levels of total cholesterol and low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides (Wako L Type Triglyceride H; Wako Pure Chemical Industries, Osaka, Japan), uric acid, creatinine (Cr), and urea nitrogen. HbA1c levels were also measured. Urinary albumin was measured in random spot urine samples by standard immunonephelometric assay. The urinary ACR was calculated. eGFR was calculated by the equation

\[ \text{eGFR (mL/min/1.73 m}^2\text{)} = 194 \times \text{Cr}^{-1.094} \times \text{age}^{-0.287} \]  
(1)

in males and

\[ \text{eGFR (mL/min/1.73 m}^2\text{)} = 194 \times \text{Cr}^{-1.094} \times \text{age}^{-0.287} \times 0.739 \]  
(2)

in females. Urinary excretions of α1-microglobulin and angiotensinogen were measured with enzyme-linked immunosorbent assay (ELISA) kits; LZ Test Eiken α1-M (Eiken Chemical Co, Tokyo, Japan), and Human Total Angiotensinogen Assay Kit (Immuno-Biological Laboratories Co, Ltd, Fujioka, Gunma, Japan).

Statistical analysis

All data are expressed as mean ± standard deviation values. Spearman correlation coefficients were used to evaluate whether urinary levels of angiotensinogen correlated with various parameters. To determine the variables independently associated with urinary levels of angiotensinogen in the patients with type 2 diabetes, multiple regression analysis was performed by including eGFR, ACR, and urinary α1-microglobulin/creatinine ratio as independent variables. Urinary levels of α1-microglobulin, angiotensinogen, and various clinical parameters in RAS inhibitors (−) and RAS inhibitors (+) groups were compared by Mann–Whitney U testing. P-values less than 0.05 were considered statistically significant. Statistical analysis was performed with IBM SPSS Statistics Base and IBM SPSS Regression (IBM Corporation, Armonk, NY, USA).

Results

Correlation of urinary angiotensinogen with urinary α1-microglobulin

The type 2 diabetes patients (n=85) with various albuminuria stages (ie, normo [n=36], micro- [n=25], and macroalbuminuria [n=24] stages) were recruited into the study and were classified into RAS inhibitors (−) and RAS inhibitors (+) groups (Table 1). At each albuminuria stage, we observed significantly different serum concentrations of total protein (demonstrated by Kruskal–Wallis test) (70.4 ± 4.3 g/L, 70.7 ± 4.8 g/L, 66.1 ± 6.5 g/L; P=0.003), albumin (42.9 ± 2.5 g/L, 41.2 ± 3.2 g/L, 35.7 ± 7.0 g/L; P=1.80 × 10^{-16}), creatinine (66.4 ± 13.3 μmol/L, 78.3 ± 26.3 μmol/L, 144.2 ± 70.3 μmol/L; P=4.86 × 10^{-16}), urea nitrogen (5.5 ± 1.5 μmol/L, 7.1 ± 2.7 μmol/L, 10.0 ± 3.8 μmol/L; P=5.92 × 10^{-6}), uric acid (305.8 ± 61.5 μmol/L, 352.8 ± 96.2 μmol/L, 396.2 ± 68.0 μmol/L; P=9.68 × 10^{-5}),
Table 1 Comparison of various parameters in the type 2 diabetes patients (n=85) with normo- (n=36), micro- (n=25), and macroalbuminuric (n=24) stages

<table>
<thead>
<tr>
<th>Number (male/female)</th>
<th>RAS inhibitors (−)</th>
<th>RAS inhibitors (+)</th>
<th>Total</th>
<th>Mann–Whitney U</th>
</tr>
</thead>
<tbody>
<tr>
<td>34 (16/18)</td>
<td>51 (33/18)</td>
<td>85 (49/36)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years ± SD)</td>
<td>63.1 ± 11.7</td>
<td>62.5 ± 11.1</td>
<td>62.9 ± 11.3</td>
<td>0.492</td>
</tr>
<tr>
<td>BMI (kg/m² ± SD)</td>
<td>24.5 ± 4.4</td>
<td>25.1 ± 4.7</td>
<td>24.9 ± 4.6</td>
<td>0.618</td>
</tr>
<tr>
<td>SBP (mmHg ± SD)</td>
<td>122.9 ± 13.4</td>
<td>128.3 ± 19.2</td>
<td>126.2 ± 17.3</td>
<td>0.216</td>
</tr>
<tr>
<td>DBP (mmHg ± SD)</td>
<td>71.2 ± 10.9</td>
<td>72.6 ± 11.2</td>
<td>72.2 ± 11.1</td>
<td>0.339</td>
</tr>
<tr>
<td>HbA₁c (% ± SD)</td>
<td>7.27 ± 0.68</td>
<td>7.33 ± 0.98</td>
<td>7.31 ± 0.87</td>
<td>0.974</td>
</tr>
<tr>
<td>Total protein (g/L ± SD)</td>
<td>70.1 ± 5.8</td>
<td>68.7 ± 5.1</td>
<td>69.3 ± 5.4</td>
<td>0.339</td>
</tr>
<tr>
<td>Albumin (g/L ± SD)</td>
<td>41.4 ± 5.8</td>
<td>39.6 ± 5.0</td>
<td>40.4 ± 5.3</td>
<td>0.032*</td>
</tr>
<tr>
<td>Cr (µmol/L ± SD)</td>
<td>81.4 ± 53.9</td>
<td>98.8 ± 50.6</td>
<td>91.9 ± 52.3</td>
<td>0.028*</td>
</tr>
<tr>
<td>UN (µmol/L ± SD)</td>
<td>7.0 ± 3.4</td>
<td>7.4 ± 3.2</td>
<td>7.3 ± 3.3</td>
<td>0.418</td>
</tr>
<tr>
<td>Uric acid (µmol/L ± SD)</td>
<td>321.3 ± 66.8</td>
<td>360.3 ± 89.8</td>
<td>344.6 ± 83.1</td>
<td>0.034*</td>
</tr>
<tr>
<td>T-Chol (mmol/L ± SD)</td>
<td>5.32 ± 1.01</td>
<td>4.77 ± 0.88</td>
<td>4.99 ± 0.97</td>
<td>0.011*</td>
</tr>
<tr>
<td>TG (mmol/L ± SD)</td>
<td>1.76 ± 1.07</td>
<td>1.84 ± 1.37</td>
<td>1.81 ± 1.26</td>
<td>0.904</td>
</tr>
<tr>
<td>HDL-C (mmol/L ± SD)</td>
<td>1.51 ± 0.45</td>
<td>1.29 ± 0.31</td>
<td>1.38 ± 0.39</td>
<td>0.041*</td>
</tr>
<tr>
<td>LDL-C (mmol/L ± SD)</td>
<td>3.03 ± 0.84</td>
<td>2.62 ± 0.74</td>
<td>2.79 ± 0.80</td>
<td>0.024</td>
</tr>
<tr>
<td>eGFR (mL/min ± SD)</td>
<td>68.5 ± 20.7</td>
<td>60.2 ± 23.0</td>
<td>63.5 ± 22.4</td>
<td>0.052</td>
</tr>
<tr>
<td>ACR (mg/gCr ± SD)</td>
<td>368.2 ± 863.8</td>
<td>489.8 ± 779.8</td>
<td>441.2 ± 812</td>
<td>0.006**</td>
</tr>
<tr>
<td>α1-microglobulin (µg/gCr ± SD)</td>
<td>7.26 ± 13.2</td>
<td>9.63 ± 10.6</td>
<td>8.68 ± 11.74</td>
<td>0.306</td>
</tr>
<tr>
<td>Angiotensinogen (µg/gCr ± SD)</td>
<td>13.3 ± 27.5</td>
<td>34.6 ± 71.5</td>
<td>26.1 ± 58.8</td>
<td>0.374</td>
</tr>
</tbody>
</table>

Notes: The patients are classified whether they are treated with or without angiotensin receptor blockers or angiotensin-converting enzyme inhibitors. *P<0.05; **P<0.01.
Abbreviations: ACR, albumin/creatinine ratio; BMI, body mass index; Cr, serum creatinine; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration ratio; HbA₁c, hemoglobin A₁c; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; RAS inhibitors (+), patients treated with angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors; RAS inhibitors (−), patients not treated with angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors; SD, standard deviation; SBP, systolic blood pressure; T-Chol, total cholesterol; TG, triglyceride; UN, serum urea nitrogen.

HDL-C (1.49 ± 0.41 mmol/L, 1.35 ± 0.31 mmol/L, 1.23 ± 0.39 mmol/L; P=0.031), and eGFR (74.5 ± 16.3 mL/min, 67.9 ± 19.2 mL/min, 42.4 ± 19.0 mL/min; P=6.66 × 10⁻⁶). Urinary proteins also significantly increased with the progression of albuminuria stages: ACR (12.7 ± 6.0 mg/gCr, 114.3 ± 72.6 mg/gCr, 1.424 ± 996 mg/gCr; P=1.81 × 10⁻¹⁰), urinary α1-microglobulin (4.24 ± 4.03 µg/gCr, 6.30 ± 5.12 µg/gCr, 17.83 ± 18.08 µg/gCr; P=8.84 × 10⁻³), and urinary angiotensinogen (6.8 ± 11.6 µg/gCr, 8.5 ± 9.9 µg/gCr, 73.3 ± 95.2 µg/gCr; P=2.88 × 10⁻⁴).

By simple regression analyses of these parameters, urinary angiotensinogen levels significantly and positively correlated with ACR (r=0.376, P=3.84 × 10⁻⁴) and urinary α1-microglobulin (r=0.734, P=1.32 × 10⁻¹⁵), while they significantly and negatively correlated with eGFR (r=0.350, P=1.02 × 10⁻³) and HDL-C (r=0.216, P=0.049) (Table 2 and Figure 1). We next investigated the correlations of urinary angiotensinogen, ACR, and urinary α1-microglobulin in various albuminuria stages. At all three albuminuria stages, urinary angiotensinogen levels did not correlate with ACR; however, urinary angiotensinogen levels significantly and highly correlated with α1-microglobulin at the normalalbuminuria stage (r=0.840, P=1.40 × 10⁻¹⁰).

Table 2 Simple correlation of urinary angiotensinogen with various clinical parameters in patients with type 2 diabetes (n=85)

| Angiotensinogen (µg/gCr) | Age (years) | BMI (kg/m²) | SBP (mmHg) | DBP (mmHg) | HbA₁c (%) | Total protein (g/L) | Albumin (g/L) | Cr (µmol/L) | UN (µmol/L) | Uric acid (µmol/L) | T-Chol (mmol/L) | TG (mmol/L) | LDL-C (mmol/L) | HDL-C (mmol/L) | eGFR (mL/min) | ACR (mg/gCr) | α1-microglobulin (µg/gCr) |
|--------------------------|-------------|-------------|------------|------------|-----------|---------------------|--------------|-------------|-------------|-------------------|----------------|-------------|----------------|---------------|---------------|-------------|---------------------------|----------------|
| r=−0.040, P=0.713       | r=−0.086, P=0.431 | r=−0.033, P=0.764 | r=−0.173, P=0.113 | r=−0.039, P=0.726 | r=−0.107, P=0.338 | r=−0.165, P=0.136 | r=−0.243, P=0.025* | r=−0.362, P=0.001** | r=−0.081, P=0.462 | r=−0.109, P=0.325 | r=−0.012, P=0.911 | r=−0.216, P=0.049* | r=−0.350, P=1.02 × 10⁻³ | r=−0.216, P=0.499* |

Notes: *P<0.05; **P<0.01. Spearman correlation coefficients are used.
Abbreviations: ACR, albumin/creatinine ratio; BMI, body mass index; Cr, serum creatinine; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration ratio; HbA₁c, hemoglobin A₁c; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; SBP, systolic blood pressure; T-Chol, total cholesterol; TG, triglyceride; UN, serum urea nitrogen.
Urinary angiotensinogen and α1-microglobulin levels unaltered in RAS inhibitors (+) and (−) groups

We next compared various clinical parameters in the RAS inhibitors (+) and (−) groups. In RAS inhibitors (+), ACR was significantly higher compared with the RAS inhibitors (−) group (368.2 ± 863.8 versus 489.8 ± 779.8 mg/gCr, \( P=0.006 \)). In contrast, there were no significant differences in urinary α1-microglobulin and angiotensinogen between the two groups (Figure 3). In clinical practice, type 2 diabetes patients with higher ACR seem to be preferentially treated with ARB or ACEI. Since urinary α1-microglobulin and angiotensinogen levels were not significantly higher in the RAS inhibitors (+) group, tubular damage and subsequent intrarenal RAS activation may be ameliorated by the administration of ARB or ACEI in RAS inhibitors (+) group.

Discussion

Proximal tubular angiotensinogen, collecting duct renin, and tubular angiotensin II type 1 receptors are positively augmented by intrarenal angiotensin (Ang) II. The infusion of \(^{125}\)I-Ang II into pigs demonstrated that steady-state concentrations of \(^{125}\)I-Ang II in cortical and medullary tissue were four-fold and twofold higher than arterial plasma and the tissue
concentrations of endogenous Ang II were 100 and 60 times higher than arterial plasma. Thus, it is suggested that most renal Ang II type 1 receptors are exposed to locally generated Ang II rather than Ang II from circulation. In rodent models, the urinary excretion of angiotensinogen in streptozotocin-induced diabetic mice 3 days after the induction of diabetes was significantly higher (349.6 ± 89.1 µg/day) than control mice (15.9 ± 2.2 µg/day) and the authors demonstrated the upregulation of angiotensinogen messenger ribonucleic acid (mRNA) and protein expression in the mouse kidneys. The

**Figure 2** Simple correlation of urinary excretion of angiotensinogen with urinary ACR and urinary α1-microglobulin in type 2 diabetes patients (n=85) in the normo- (n=36), micro- (n=25), and macroalbuminuric (n=24) stages. **Note:** Spearman correlation coefficients are used. A, C and E, urinary ACR. B, D, and F, urinary α1-microglobulin. A and B, normoalbuminuria. C and D, microalbuminuria. E and F, macroalbuminuria. **Abbreviation:** ACR, albumin/creatinine ratio.
Table 3 Multiple linear regression analysis using urinary angiotensinogen as a dependent variable in patients with type 2 diabetes (n=85)

<table>
<thead>
<tr>
<th>Dependent variable</th>
<th>Independent variable</th>
<th>Unstandardized coefficient</th>
<th>Standardized coefficient</th>
<th>t-value</th>
<th>P-value</th>
<th>Adjusted R²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1</td>
<td>Urinary angiotensinogen (µg/gCr)</td>
<td>0.001 0.007</td>
<td>0.014 0.142</td>
<td>0.888 0.928</td>
<td>0.519</td>
<td></td>
</tr>
<tr>
<td>Model 2</td>
<td>Urinary angiotensinogen (µg/gCr)</td>
<td>3.668 0.374</td>
<td>0.732 9.800</td>
<td>1.64×10⁻¹⁵</td>
<td>0.531</td>
<td></td>
</tr>
</tbody>
</table>

Notes: Estimated eGFR (mL/min), ACR (mg/gCr), and α1-microglobulin (µg/gCr) are used as independent variables in multiple linear regression analysis. In Model 1, all parameters are included; stepwise multiple linear regression analysis is performed in Model 2. **P<0.01.

Abbreviations: ACR, albumin/creatinine ratio; eGFR, estimated glomerular filtration ratio.

Figure 3 Urinary ACR, eGFR, urinary excretion of α1-microglobulin, and urinary excretion of angiotensinogen in patients with various stages of diabetic nephropathy (n=85).

Notes: Urinary levels of albumin, α1-microglobulin, angiotensinogen, and eGFR in RAS inhibitors (−) and RAS inhibitors (+) groups are compared by Mann–Whitney U.


Abbreviations: ACR, albumin/creatinine ratio; eGFR, estimated glomerular filtration ratio; RAS, renin–angiotensin system.
data suggested that urinary excretion of angiotensinogen is a biomarker for the activation of RAS in the kidney under diabetic states. In humans, plasma angiotensinogen reaches urine via glomerular filtration, like albumin, and the normal urinary angiotensinogen levels in humans is \(-0.2\) pmol/mL, versus \(-1,200\) pmol/mL in plasma. Thus, the urinary angiotensinogen levels range from 0.01% to 0.1% of the plasma levels in humans. In contrast, urinary angiotensinogen levels in rodents are much higher and range from 0.1–400 pmol/mL, implying that the urinary angiotensinogen levels in rodents are sometimes higher than their plasma levels. Less than 100-fold higher urinary angiotensinogen levels in rodents suggested the concept that urinary angiotensinogen is exclusively plasma-derived in humans, whereas it reflects angiotensinogen release from renal tissues, possibly proximal tubules, in rodents. Since albumin is produced in the liver and urinary albumin is entirely derived from plasma, the comparison of urinary albumin and angiotensinogen would demonstrate to what degree urinary angiotensinogen is plasma derived in humans. In fact, several studies demonstrated high correlation between urinary albumin and angiotensinogen without exception.

In the current investigation, we simultaneously measured ACR, urinary \(\alpha\)-1-microglobulin, and urinary angiotensinogen levels in the patients with type 2 diabetes and various stages of diabetic nephropathy. Urinary angiotensinogen levels significantly and positively correlated with ACR \((r=0.376, P=3.84 \times 10^{-4})\) as previously reported, and we also found further high correlation with urinary \(\alpha\)-1-microglobulin \((r=0.734, P=1.32 \times 10^{-15})\). High correlation of urinary \(\alpha\)-1-microglobulin and angiotensinogen levels was also found both in microalbuminuria and microalbuminuria stages; however, ACR did not show significant correlation with urinary angiotensinogen at normo-, micro-, and macroalbuminuria stages. The high correlation between urinary \(\alpha\)-1-microglobulin and angiotensinogen levels at the normoalbuminuric stage supported the concept that tubular damage promotes the intrarenal RAS activation and production of tubular angiotensinogen, since the normoalbuminuric patients would not be expected to have leakage of plasma angiotensinogen into urinary space.

Urinary \(\alpha\)-1-microglobulin is filtered freely through glomerular capillaries and reabsorbed by the proximal tubules. Thus, urinary \(\alpha\)-1-microglobulin is a marker for proximal tubule dysfunction, and increased levels of urinary \(\alpha\)-1-microglobulin have been reported in normoalbuminuric patients with type 1 diabetes and type 2 diabetes. The assessment of proximal tubule dysfunction in the course of diabetes by urinary \(\alpha\)-1-microglobulin allows the early diagnosis of diabetic nephropathy prior to the appearance of microalbuminuria, and also predicts the progression of diabetic nephropathy. Plasma angiotensinogen is filtered through glomerular capillaries, and urinary angiotensinogen is mainly derived from plasma. Subsequently, urinary angiotensinogen is largely removed via endocytotic uptake in tubules in a megalin-dependent manner. Endocytotic angiotensinogen is subsequently degraded and the contents of angiotensinogen in the proximal convoluted tubules highly correlated with plasma levels of angiotensinogen. Thus, previous studies also support the idea that urinary excretion of angiotensinogen reflects not only abnormalities of glomerular filtration barrier but also proximal tubular functions. It has been reported that urinary angiotensinogen levels increase before glomerular injuries in the patients as well as in rodents.

Yamamoto et al demonstrated that administration of losartan reduced urinary and plasma angiotensinogen levels in the patients with chronic kidney disease. In hypertensive patients with preserved kidney function, RAS blockers decreased the urinary angiotensinogen, and the decrease was comparable to that in urinary albumin. Furthermore, in immunoglobulin A nephropathy, treatment with valsartan also reduced urinary angiotensinogen. As in various kidney diseases, RAS inhibitors suppressed urinary angiotensinogen levels with type 2 diabetes. One can speculate that reduction of urinary angiotensinogen by RAS blockers is due to the amelioration of glomerular hyperfiltration and suppression of enhanced filtration of various proteins, including angiotensinogen, through glomerular capillaries. Although ACR was higher in the RAS inhibitors (+) group, urinary \(\alpha\)-1-microglobulin and angiotensinogen were not significantly increased in the RAS inhibitors (+) group. Thus, we speculate that RAS inhibitors may ameliorate the tubular injuries and intrarenal RAS activation, which was reflected by the lack of significant increase in urinary \(\alpha\)-1-microglobulin and angiotensinogen levels.

**Conclusion**

In summary, we demonstrated the significant and positive correlation of urinary angiotensinogen levels with ACR and urinary \(\alpha\)-1-microglobulin, and the negative correlation with eGFR. In a multiple regression analysis including all parameters (eGFR, ACR and urinary \(\alpha\)-1-microglobulin) as independent variables, only urinary \(\alpha\)-1-microglobulin was a significant independent variable. The current cross-sectional clinical study revealed that urinary angiotensinogen is a marker
for tubular injuries of the early stage of diabetic nephropathy in patients with type 2 diabetes. Since the current study was a cross-sectional clinical investigation, the significance of urinary angiotensinogen for predicting long-term course of diabetic nephropathy is still unknown. In future studies, the significance of urinary angiotensinogen in predicting the progression of diabetic nephropathy needs to be demonstrated.

Acknowledgments
This work was supported by JSPS Grant-in-Aid for Scientific Research, Grants 23390241 and 25126716, and by the Health Labour Sciences Research Grant, Japan. KI, TT, and JW designed and performed most of the experiments. JE, AN, ST, KM, DO, TT, and AK recruited the patients. All authors contributed to conception and design, acquisition of data, or analysis and interpretation of data. In addition, all authors drafted the article, revised it critically for important intellectual content and gave final approval of the version to be published.

Disclosure
JW is a consultant for Boehringer Ingelheim, receives speaker honoraria from Novartis. HM is a consultant for Teijin, AbbVie and Astellas, receives speaker honoraria from Astellas, MSD, Takeda, and Tanabe Mitsubishi, and receives grant support from Astellas, Daichi Sankyo, Dainippon Sumitomo, MSD, Novo Nordisk and Takeda. DO and AN belong to the Department of Diabetic Nephropathy, which is funded by Boehringer Ingelheim. The authors report no conflicts of interest in this work.

References